The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer’s Disease

Alzheimer’s disease (AD) is one of the most prominent neurodegenerative diseases, which impairs cognitive function in afflicted individuals. AD results in gradual decay of neuronal function as a consequence of diverse degenerating events. Several neuroimmune players (such as cytokines and growth factors that are key players in maintaining CNS homeostasis) turn aberrant during crosstalk between the innate and adaptive immunities. This aberrance underlies neuroinflammation and drives neuronal cells toward apoptotic decline. Neuroinflammation involves microglial activation and has been shown to exacerbate AD. This review attempted to elucidate the role of cytokines, growth factors, and associated mechanisms implicated in the course of AD, especially with neuroinflammation. We also evaluated the propensities and specific mechanism(s) of cytokines and growth factors impacting neuron upon apoptotic decline and further shed light on the availability and accessibility of cytokines across the blood-brain barrier and choroid plexus in AD pathophysiology. The pathogenic and the protective roles of macrophage migration and inhibitory factors, neurotrophic factors, hematopoietic-related growth factors, TAU phosphorylation, advanced glycation end products, complement system, and glial cells in AD and neuropsychiatric pathology were also discussed. Taken together, the emerging roles of these factors in AD pathology emphasize the importance of building novel strategies for an effective therapeutic/neuropsychiatric management of AD in clinics.

[1]  P. Reddy,et al.  Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic , 2021, Molecular Neurobiology.

[2]  Vishal C. Kalel,et al.  COVID-19, Neuropathology, and Aging: SARS-CoV-2 Neurological Infection, Mechanism, and Associated Complications , 2021, Frontiers in Aging Neuroscience.

[3]  P. Reddy,et al.  The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus , 2021, Cells.

[4]  S. Rivest,et al.  Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls , 2021, Molecular Psychiatry.

[5]  P. Reddy,et al.  Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy , 2021, Ageing Research Reviews.

[6]  B. Casali,et al.  Microglial Function and Regulation during Development, Homeostasis and Alzheimer’s Disease , 2021, Cells.

[7]  C. Norris,et al.  Reactive astrocytes: The nexus of pathological and clinical hallmarks of Alzheimer’s disease , 2021, Ageing Research Reviews.

[8]  A. Moin,et al.  Modulating neuroinflammation in neurodegeneration-related dementia: can microglial toll-like receptors pull the plug? , 2021, Metabolic Brain Disease.

[9]  J. Włodarczyk,et al.  Cellular Senescence in Brain Aging , 2021, Frontiers in Aging Neuroscience.

[10]  T. Theoharides,et al.  Neuroinflammation in Alzheimer's disease and beneficial action of luteolin , 2021, BioFactors.

[11]  T. Yamashita,et al.  Complement cascade functions during brain development and neurodegeneration , 2021, The FEBS journal.

[12]  J. Sabbatinelli,et al.  Connecting vascular aging and frailty in Alzheimer’s disease , 2021, Mechanisms of Ageing and Development.

[13]  R. Kandimalla,et al.  Mitochondrial dysfunction, mitophagy, and role of dynamin‐related protein 1 in Alzheimer's disease , 2021, Journal of neuroscience research.

[14]  Puneet Kumar,et al.  Neuroprotection through G-CSF: recent advances and future viewpoints , 2021, Pharmacological Reports.

[15]  V. Andrisano,et al.  Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery? , 2020, Journal of medicinal chemistry.

[16]  Song Li,et al.  New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease , 2020, Acta Pharmacologica Sinica.

[17]  R. Morishita,et al.  Insight into the Role of Angiopoietins in Ageing-Associated Diseases , 2020, Cells.

[18]  G. Šimić,et al.  The Association between TNF-alpha, IL-1 alpha and IL-10 with Alzheimer's Disease. , 2020, Current Alzheimer research.

[19]  M. Noroozian,et al.  Do serum GDNF levels correlate with severity of Alzheimer’s disease? , 2020, Neurological Sciences.

[20]  S. Kaul,et al.  Identification of Caffeic Acid Phenethyl Ester (CAPE) as a Potent Neurodifferentiating Natural Compound That Improves Cognitive and Physiological Functions in Animal Models of Neurodegenerative Diseases , 2020, Frontiers in Aging Neuroscience.

[21]  H. Braak,et al.  Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[22]  E. Khedr,et al.  Cognitive Impairment, P300, and Transforming Growth Factor β1 in Different Forms of Dementia. , 2020, Journal of Alzheimer's disease : JAD.

[23]  C. Geula,et al.  Accumulation of neurofibrillary tangles and activated microglia is associated with lower neuron densities in the aphasic variant of Alzheimer’s disease , 2020, Brain pathology.

[24]  G. Corso,et al.  Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features , 2020, Scientific Reports.

[25]  E. Tai,et al.  Shared signaling pathways in Alzheimer’s and metabolic disease may point to new treatment approaches , 2020, The FEBS journal.

[26]  X-F Li,et al.  Progress in the study of markers related to glioma prognosis. , 2020, European review for medical and pharmacological sciences.

[27]  J. Lukens,et al.  The role of innate immunity in Alzheimer's disease , 2020, Immunological reviews.

[28]  Yitao Wang,et al.  NRBF2 is a RAB7 effector required for autophagosome maturation and mediates the association of APP-CTFs with active form of RAB7 for degradation , 2020, Autophagy.

[29]  T. Behl,et al.  Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease. , 2020, IUBMB life.

[30]  D. Morgan,et al.  CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy , 2020, Frontiers in Immunology.

[31]  B. Rossi,et al.  In vitro Models of Neurodegenerative Diseases , 2020, Frontiers in Cell and Developmental Biology.

[32]  B. Winblad,et al.  Quantifying and Describing the Natural History and Costs of Alzheimer’s Disease and Effects of Hypothetical Interventions , 2020, Journal of Alzheimer's disease : JAD.

[33]  N. Toschi,et al.  A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease , 2020, Frontiers in Immunology.

[34]  A. Giovino,et al.  Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects , 2020, Oxidative medicine and cellular longevity.

[35]  S. Di Nuovo,et al.  The cytokine network in the pathogenesis of major depressive disorder. Close to translation? , 2020, Autoimmunity reviews.

[36]  Zhi-Yong Xiao,et al.  Angiopoietin-1 accelerates Alzheimer's disease via FOXA2/PEN2/APP pathway in APP/PS1 mice. , 2020, Life sciences.

[37]  A. Tong,et al.  The role of astrocytes in oxidative stress of central nervous system: A mixed blessing , 2020, Cell proliferation.

[38]  A. Tenner Complement-Mediated Events in Alzheimer’s Disease: Mechanisms and Potential Therapeutic Targets , 2020, The Journal of Immunology.

[39]  Nicholas E. Propson,et al.  Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. , 2020, The Journal of clinical investigation.

[40]  Michael R. Elliott,et al.  IL-1β-driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia , 2019, Journal of Neuroinflammation.

[41]  X. Yao,et al.  Neurotrophin receptor p75 mediates amyloid β-induced tau pathology , 2019, Neurobiology of Disease.

[42]  M. Hamblin,et al.  Neural stem cell therapy for neurovascular injury in Alzheimer's disease , 2019, Experimental Neurology.

[43]  M. Sabbagh,et al.  The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis , 2019, Alzheimer's & Dementia.

[44]  Yuquan Wei,et al.  Epigenetic regulation of macrophages: from homeostasis maintenance to host defense , 2019, Cellular & Molecular Immunology.

[45]  K. Iverfeldt,et al.  Phosphorylation of the amyloid precursor protein (APP) at Ser-675 promotes APP processing involving meprin β , 2019, The Journal of Biological Chemistry.

[46]  M. Gurney,et al.  Tumor Necrosis Factor (TNF) Blocking Agents are Associated with Lower Risk for Alzheimer’s Disease in Patients with Rheumatoid Arthritis and Psoriasis , 2019 .

[47]  Sung Hoon Baik,et al.  Mimicry of Central-Peripheral Immunity in Alzheimer's Disease and Discovery of Neurodegenerative Roles in Neutrophil , 2019, Front. Immunol..

[48]  J. Plemel,et al.  Central Nervous System Remyelination: Roles of Glia and Innate Immune Cells , 2019, Front. Mol. Neurosci..

[49]  K. Nie,et al.  Macrophage Migration Inhibitory Factor Mediates Neuroprotective Effects by Regulating Inflammation, Apoptosis and Autophagy in Parkinson's Disease , 2019, Neuroscience.

[50]  M. Wolf,et al.  FGF23 at the crossroads of phosphate, iron economy and erythropoiesis , 2019, Nature Reviews Nephrology.

[51]  L. Khorsandi,et al.  The effect of triiodothyronine on the hippocampal long-term potentiation in an animal model of the Alzheimer's disease: The role of BDNF and reelin , 2019, Neurology, Psychiatry and Brain Research.

[52]  A. Cuello Editorial: The Involvement of NGF in the Alzheimer's Pathology , 2019, Front. Neurosci..

[53]  R. Biringer The Role of Eicosanoids in Alzheimer’s Disease , 2019, International journal of environmental research and public health.

[54]  A. Israelson,et al.  AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS , 2019, Proceedings of the National Academy of Sciences.

[55]  C. Matute,et al.  Aβ oligomers promote oligodendrocyte differentiation and maturation via integrin β1 and Fyn kinase signaling , 2019, Cell Death & Disease.

[56]  M. Naveed,et al.  Cerebrovascular inflammation: A critical trigger for neurovascular injury? , 2019, Neurochemistry International.

[57]  A. Kuhad,et al.  Quinolinic Acid and Nuclear Factor Erythroid 2-Related Factor 2 in Depression: Role in Neuroprogression , 2019, Front. Pharmacol..

[58]  K. Prasad AGE–RAGE stress: a changing landscape in pathology and treatment of Alzheimer’s disease , 2019, Molecular and Cellular Biochemistry.

[59]  R. Faull,et al.  Vascular Dysfunction in Alzheimer’s Disease: A Prelude to the Pathological Process or a Consequence of It? , 2019, Journal of clinical medicine.

[60]  J. Palha,et al.  Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline , 2019, Neurobiology of Aging.

[61]  D. Michaelson,et al.  ApoE4: an emerging therapeutic target for Alzheimer’s disease , 2019, BMC Medicine.

[62]  V. Sharma,et al.  Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease , 2019, Inflammopharmacology.

[63]  R. Yan,et al.  A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment , 2019, CNS Drugs.

[64]  M. Eriksdotter,et al.  Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF , 2019, Front. Neurosci..

[65]  Xiangdong Gao,et al.  Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer’s disease , 2019, Redox biology.

[66]  B. Vincent,et al.  Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer's disease , 2019, Medicinal research reviews.

[67]  M. Alshammari,et al.  Neuroinflammatory Cytokines Induce Amyloid Beta Neurotoxicity through Modulating Amyloid Precursor Protein Levels/Metabolism , 2018, BioMed research international.

[68]  A. Alonso,et al.  Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability , 2018, Front. Cell. Neurosci..

[69]  L. Estrada,et al.  Transforming Growth Factor Beta Type I Role in Neurodegeneration: Implications for Alzheimer´s Disease. , 2018, Current protein & peptide science.

[70]  E. Newcombe,et al.  Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease , 2018, Journal of Neuroinflammation.

[71]  B. Lamb,et al.  Inflammation as a central mechanism in Alzheimer's disease , 2018, Alzheimer's & dementia.

[72]  L. Tan,et al.  Innate immune activation in Alzheimer's disease. , 2018, Annals of translational medicine.

[73]  Xu Wang,et al.  Emerging Roles of Astrocytes in Neuro-Vascular Unit and the Tripartite Synapse With Emphasis on Reactive Gliosis in the Context of Alzheimer’s Disease , 2018, Front. Cell. Neurosci..

[74]  Xiaoyan Qin,et al.  Postmortem Brain, Cerebrospinal Fluid, and Blood Neurotrophic Factor Levels in Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2018, Journal of Molecular Neuroscience.

[75]  J. Kamińska,et al.  CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration. , 2018, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[76]  M. Awais,et al.  IP-10 Promotes Blood–Brain Barrier Damage by Inducing Tumor Necrosis Factor Alpha Production in Japanese Encephalitis , 2018, Front. Immunol..

[77]  Shu-Qun Liu,et al.  Suppression of MIF-induced neuronal apoptosis may underlie the therapeutic effects of effective components of Fufang Danshen in the treatment of Alzheimer's disease , 2018, Acta Pharmacologica Sinica.

[78]  P. Reddy,et al.  Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer’s disease , 2018, Human molecular genetics.

[79]  A. Tolkovsky,et al.  Neuronal Cell Death. , 2018, Physiological reviews.

[80]  Francesc X. Soriano,et al.  Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications , 2018, Journal of psychopharmacology.

[81]  P. Lewczuk,et al.  Amyloid β oligomers (AβOs) in Alzheimer’s disease , 2018, Journal of Neural Transmission.

[82]  A. Atanasov,et al.  Autophagy and Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Implications , 2018, Front. Aging Neurosci..

[83]  M. Fukaya,et al.  Dysfunctional autophagy following exposure to pro-inflammatory cytokines contributes to pancreatic β-cell apoptosis , 2018, Cell Death & Disease.

[84]  L. Du,et al.  Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target , 2017, Molecular Neurobiology.

[85]  T. Numakawa,et al.  Actions of Brain-Derived Neurotrophic Factor and Glucocorticoid Stress in Neurogenesis , 2017, International journal of molecular sciences.

[86]  M. Tomás,et al.  Oxidative stress and the amyloid beta peptide in Alzheimer’s disease , 2017, Redox biology.

[87]  S. Kaul,et al.  2,3-Dihydro-3β-methoxy Withaferin-A Protects Normal Cells against Stress: Molecular Evidence of Its Potent Cytoprotective Activity. , 2017, Journal of natural products.

[88]  M. Mesulam,et al.  WITHDRAWN: Revisiting the cholinergic hypothesis in Alzheimer's disease: Emerging evidence from translational and clinical research. , 2017, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[89]  Z. Yue,et al.  NRBF2 is involved in the autophagic degradation process of APP-CTFs in Alzheimer disease models , 2017, Autophagy.

[90]  S. Tsai Effects of interleukin-1beta polymorphisms on brain function and behavior in healthy and psychiatric disease conditions. , 2017, Cytokine & growth factor reviews.

[91]  K. Gomes,et al.  Alzheimer’s disease and cytokine IL-10 gene polymorphisms: is there an association? , 2017, Arquivos de Neuro-Psiquiatria.

[92]  Jahan B. Ghasemi,et al.  In Silico Studies in Drug Research Against Neurodegenerative Diseases , 2017, Current neuropharmacology.

[93]  Winnie S. Liang,et al.  Necroptosis activation in Alzheimer's disease , 2017, Nature Neuroscience.

[94]  J. Little,et al.  High Glucose Enhances Neurotoxicity and Inflammatory Cytokine Secretion by Stimulated Human Astrocytes. , 2017, Current Alzheimer research.

[95]  A. Ramírez,et al.  [Search for risk genes in Alzheimer's disease]. , 2017, Der Nervenarzt.

[96]  J. Wojcik,et al.  Markers of neuroinflammation associated with Alzheimer’s disease pathology in older adults , 2017, Brain, Behavior, and Immunity.

[97]  J. Ojala,et al.  The Role of Interleukin-18, Oxidative Stress and Metabolic Syndrome in Alzheimer’s Disease , 2017, Journal of clinical medicine.

[98]  Eugenia Trushina,et al.  Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease , 2017, Journal of Alzheimer's disease : JAD.

[99]  A. Çeti̇n,et al.  SDF-1/CXCL12 and CXCR4 gene variants, and elevated serum SDF-1 levels are associated with preeclampsia , 2017, Hypertension in pregnancy.

[100]  I. Martin Resveratrol for Alzheimer’s disease? , 2017, Science Translational Medicine.

[101]  Debomoy K Lahiri,et al.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. , 2016, Current Alzheimer research.

[102]  R. Bucala,et al.  Endogenous macrophage migration inhibitory factor reduces the accumulation and toxicity of misfolded SOD1 in a mouse model of ALS , 2016, Proceedings of the National Academy of Sciences.

[103]  M. Grilli,et al.  Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis. , 2016, CNS & neurological disorders drug targets.

[104]  M. Anderova,et al.  Glial Cells - The Key Elements of Alzheimer´s Disease. , 2016, Current Alzheimer research.

[105]  K. Blennow,et al.  Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation , 2016, Scientific Reports.

[106]  D. Brites,et al.  Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation , 2015, Front. Cell. Neurosci..

[107]  P. Jendelová,et al.  Alzheimer’s Disease: Mechanism and Approach to Cell Therapy , 2015, International journal of molecular sciences.

[108]  Andreas U. Monsch,et al.  The 12 Years Preceding Mild Cognitive Impairment Due to Alzheimer’s Disease: The Temporal Emergence of Cognitive Decline , 2015, Journal of Alzheimer's disease : JAD.

[109]  R. Bucala,et al.  Deficiency of macrophage migration inhibitory factor attenuates tau hyperphosphorylation in mouse models of Alzheimer’s disease , 2015, Journal of Neuroinflammation.

[110]  E. Diamanti-Kandarakis,et al.  Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management , 2015, Diabetes, metabolic syndrome and obesity : targets and therapy.

[111]  Burkhard Becher,et al.  Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.

[112]  Anil Kumar,et al.  A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.

[113]  A. Descoteaux,et al.  Macrophage Cytokines: Involvement in Immunity and Infectious Diseases , 2014, Front. Immunol..

[114]  I. Bautmans,et al.  Effect of advanced glycation end product intake on inflammation and aging: a systematic review. , 2014, Nutrition reviews.

[115]  Steffen Jung,et al.  Opposing Effects of Membrane-Anchored CX3CL1 on Amyloid and Tau Pathologies via the p38 MAPK Pathway , 2014, The Journal of Neuroscience.

[116]  Teng Jiang,et al.  Microglia in Alzheimer's Disease , 2014, BioMed research international.

[117]  S. Gauthier,et al.  Patterns of Cognitive Decline Prior to Dementia in Persons with Mild Cognitive Impairment , 2014, Alzheimer's & Dementia.

[118]  A. Biswas,et al.  Raised serum proinflammatory cytokines in Alzheimer's disease with depression. , 2014, Aging and disease.

[119]  F. Terro,et al.  Involvement of interleukin-1β in the autophagic process of microglia: relevance to Alzheimer’s disease , 2013, Journal of Neuroinflammation.

[120]  F. Espíndola,et al.  Myosins Are Differentially Expressed under Oxidative Stress in Chronic Streptozotocin-Induced Diabetic Rat Brains , 2013, ISRN neuroscience.

[121]  M. Philipp,et al.  Cytokines and Chemokines at the Crossroads of Neuroinflammation, Neurodegeneration, and Neuropathic Pain , 2013, Mediators of inflammation.

[122]  P. Saharinen,et al.  Angiopoietin signaling in the vasculature. , 2013, Experimental cell research.

[123]  Li Liu,et al.  Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1 in primary neurons by sphingomyelinases , 2013, Neurobiology of Aging.

[124]  J. Morillas-Ruiz,et al.  A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines , 2012, TheScientificWorldJournal.

[125]  F. LaFerla,et al.  Blocking IL-1 Signaling Rescues Cognition, Attenuates Tau Pathology, and Restores Neuronal β-Catenin Pathway Function in an Alzheimer’s Disease Model , 2011, The Journal of Immunology.

[126]  Ping Wang,et al.  VEGF-induced angiogenesis ameliorates the memory impairment in APP transgenic mouse model of Alzheimer's disease. , 2011, Biochemical and biophysical research communications.

[127]  Alberto Pupi,et al.  PET/CT in diagnosis of dementia , 2011, Annals of the New York Academy of Sciences.

[128]  M. Mullan,et al.  Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer's disease. , 2011, Cytokine.

[129]  L. Lue,et al.  RAGE‐dependent signaling in microglia contributes to neuroinflammation, Aβ accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[130]  F. Jessen,et al.  The Role of Macrophage Migration Inhibitory Factor in Alzheimer’s Disease , 2010, Molecular medicine.

[131]  L. Schultz,et al.  Intraventricular infusion of hyperosmolar dextran induces hydrocephalus: a novel animal model of hydrocephalus , 2009, Cerebrospinal Fluid Research.

[132]  A. Clayton,et al.  The blood brain barrier and the role of cytokines in neuropsychiatry. , 2009, Psychiatry (Edgmont (Pa. : Township)).

[133]  Jae Won Chung,et al.  Impairment of Instrumental Activities of Daily Living in Patients with Mild Cognitive Impairment , 2009, Psychiatry investigation.

[134]  M. Kivipelto,et al.  Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention , 2009, Dialogues in clinical neuroscience.

[135]  F. Jessen,et al.  Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. , 2009, Journal of psychiatric research.

[136]  D. Geschwind,et al.  Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease , 2009, Nature Medicine.

[137]  N. Durany,et al.  Oxidative stress in Alzheimer disease , 2009, Cell adhesion & migration.

[138]  C. Lemere,et al.  Complement C3 Deficiency Leads to Accelerated Amyloid β Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice , 2008, The Journal of Neuroscience.

[139]  S. Kitazume,et al.  Interleukin‐1β up‐regulates TACE to enhance α‐cleavage of APP in neurons: resulting decrease in Aβ production , 2008 .

[140]  L. Buée,et al.  Neurotrophic factors in Alzheimer’s disease: role of axonal transport , 2008, Genes, brain, and behavior.

[141]  H. Neumann,et al.  Neuronal ‘On’ and ‘Off’ signals control microglia , 2007, Trends in Neurosciences.

[142]  C. Masters,et al.  Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau , 2007, PloS one.

[143]  W. Pan,et al.  Cytokines Interact with the Blood‐Brain Barrier , 2007 .

[144]  R. Dantzer,et al.  Named Series: Twenty Years of Brain, Behavior, and Immunity Twenty years of research on cytokine-induced sickness behavior , 2007 .

[145]  P. Lucassen,et al.  Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus , 2006, Neurobiology of Disease.

[146]  R. N. Saha,et al.  Signals for the induction of nitric oxide synthase in astrocytes , 2006, Neurochemistry International.

[147]  S. Bandyopadhyay,et al.  Interleukin‐1α stimulates non‐amyloidogenic pathway by α‐secretase (ADAM‐10 and ADAM‐17) cleavage of APP in human astrocytic cells involving p38 MAP kinase , 2006 .

[148]  Hirohisa Tajima,et al.  Neuronal cell death in Alzheimer's disease and a neuroprotective factor, humanin. , 2006, Current neuropharmacology.

[149]  S. Barger,et al.  Journal of Neuroinflammation Interleukin-1 Mediates Alzheimer and Lewy Body Pathologies , 2022 .

[150]  S. Donnini,et al.  FGF-2 overexpression opposes the beta amyloid toxic injuries to the vascular endothelium , 2006, Cell Death and Differentiation.

[151]  K. Maiese,et al.  Erythropoietin Requires NF-κB and its Nuclear Translocation to Prevent Early and Late Apoptotic Neuronal Injury During β-Amyloid Toxicity , 2005 .

[152]  M. Schultzberg,et al.  Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease , 2005, Neurochemistry International.

[153]  V. Mathura,et al.  Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease , 2005, Journal of Neuroinflammation.

[154]  S. Roßner,et al.  Alzheimer's disease β‐secretase BACE1 is not a neuron‐specific enzyme , 2005 .

[155]  K. Fuxe,et al.  Nicotine-induced FGF-2 mRNA in rat brain is preserved during aging , 2004, Neurobiology of Aging.

[156]  J. Thyberg,et al.  Comparative Evaluation of FGF-2–, VEGF-A–, and VEGF-C–Induced Angiogenesis, Lymphangiogenesis, Vascular Fenestrations, and Permeability , 2004, Circulation research.

[157]  C. Dinarello,et al.  The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[158]  Lin Xie,et al.  Increased hippocampal neurogenesis in Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[159]  T. Nabeshima,et al.  Brain-derived neurotrophic factor/TrkB signaling in memory processes. , 2003, Journal of pharmacological sciences.

[160]  T. Wyss-Coray,et al.  Adult mouse astrocytes degrade amyloid-β in vitro and in situ , 2003, Nature Medicine.

[161]  J. Foidart,et al.  Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression , 2002, Neuropathology and applied neurobiology.

[162]  C. Winter,et al.  A microdialysis method for the recovery of IL-1β, IL-6 and nerve growth factor from human brain in vivo , 2002, Journal of Neuroscience Methods.

[163]  M Chopp,et al.  Angiopoietin-1 reduces cerebral blood vessel leakage and ischemic lesion volume after focal cerebral embolic ischemia in mice , 2002, Neuroscience.

[164]  John D Lambris,et al.  Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[165]  Claudio Soto,et al.  Reduction of amyloid load and cerebral damage in transgenic mouse model of Alzheimer's disease by treatment with a β‐sheet breaker peptide , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[166]  A. Tenner Complement in Alzheimer’s disease: opportunities for modulating protective and pathogenic events , 2001, Neurobiology of Aging.

[167]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[168]  I. Zachary Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. , 2001, American journal of physiology. Cell physiology.

[169]  C. Hock,et al.  Alterations in Trk A, Trk B and Trk C Receptor Immunoreactivities in Parietal Cortex and Cerebellum in Alzheimer’s Disease , 2000, European Neurology.

[170]  G. Siegel,et al.  Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain , 2000, Brain Research Reviews.

[171]  R Brookmeyer,et al.  Age-specific incidence rates of Alzheimer’s disease , 2000, Neurology.

[172]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[173]  L. Mucke,et al.  Alzheimer's Disease‐like Cerebrovascular Pathology in Transforming Growth Factor‐β1 Transgenic Mice and Functional Metabolic Correlates , 2000, Annals of the New York Academy of Sciences.

[174]  J. LaManna,et al.  Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. , 1998, Brain research. Molecular brain research.

[175]  Y. Chong Effect of a carboxy-terminal fragment of the Alzheimer's amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells. , 1997, Life sciences.

[176]  A. Roberts,et al.  TGF-β: A Critical Modulator of Immune Cell Function☆ , 1997 .

[177]  Yong Ming Li,et al.  Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease , 1997, Neuroscience Letters.

[178]  S. Skaper,et al.  Nerve growth factor: from neurotrophin to neurokine , 1996, Trends in Neurosciences.

[179]  C. Brosnan,et al.  Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1beta and IL-1 receptor antagonist. , 1996, Journal of immunology.

[180]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[181]  C. Ibáñez,et al.  Synergistic Trophic Actions on Rat Basal Forebrain Neurons Revealed by a Synthetic NGF/BDNF Chimaeric Molecule , 1995, The European journal of neuroscience.

[182]  B. Yankner,et al.  β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding , 1995, Neuron.

[183]  W. Tourtellotte,et al.  Transforming growth factor beta in Alzheimer's disease , 1994, Clinical and diagnostic laboratory immunology.

[184]  W. Banks,et al.  Murine tumor necrosis factor alpha is transported from blood to brain in the mouse , 1993, Journal of Neuroimmunology.

[185]  R. Levy,et al.  On certain peculiar diseases of old age , 1991, History of psychiatry.

[186]  T. Isbir,et al.  Potential Protective Role of SDF-1 and CXCR4 Gene Variants in the Development of Dementia. , 2020, Psychiatria Danubina.

[187]  Đ. Miljković,et al.  MIF and insulin: Lifetime companions from common genesis to common pathogenesis. , 2019, Cytokine.

[188]  D. Muresanu,et al.  Severity-Related Increase and Cognitive Correlates of Serum VEGF Levels in Alzheimer's Disease ApoE4 Carriers. , 2018, Journal of Alzheimer's disease : JAD.

[189]  Harald Hampel,et al.  Revisiting the Cholinergic Hypothesis in Alzheimer’s Disease: Emerging Evidence from Translational and Clinical Research , 2018, The Journal of Prevention of Alzheimer's Disease.

[190]  S. Joshi,et al.  Alzheimer’s Disease:Intracellular Beta Amyloid Completes the Irreversible Pathway from Spirochetes to Biofilms to Beta Amyloid to Hyperphosphorylated Tau Protein , 2018 .

[191]  S. Sattler The Role of the Immune System Beyond the Fight Against Infection. , 2017, Advances in experimental medicine and biology.

[192]  H. Wagner,et al.  Suche nach Risikogenen bei der Alzheimer-Erkrankung , 2017, Der Nervenarzt.

[193]  C. Laske,et al.  Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies. , 2014, Current Alzheimer research.

[194]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[195]  M. Murphy,et al.  Alzheimer's disease and the amyloid-beta peptide. , 2010, Journal of Alzheimer's disease : JAD.

[196]  C. Laske,et al.  Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[197]  W. Oertel,et al.  Immunization as treatment for Parkinson's disease. , 2009, Journal of neural transmission. Supplementum.

[198]  C. Laske,et al.  Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with early Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[199]  S. Kitazume,et al.  Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. , 2008, Journal of neurochemistry.

[200]  A. Volterra,et al.  Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation. , 2007, International review of neurobiology.

[201]  S. Bandyopadhyay,et al.  Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. , 2006, Journal of neuroscience research.

[202]  Robert S Negrin,et al.  Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. , 2005, Annual review of medicine.

[203]  K. Maiese,et al.  Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. , 2005, Current neurovascular research.

[204]  T. Wyss-Coray,et al.  Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. , 2003, Nature medicine.

[205]  A. Roberts,et al.  TGF-beta: a critical modulator of immune cell function. , 1997, Clinical immunology and immunopathology.

[206]  M. Maes Α Review on the Acute Phase Response in Major Depression , 1993, Reviews in the neurosciences.

[207]  R. Coffman,et al.  Lymphokine control of in vivo immunoglobulin isotype selection. , 1990, Annual review of immunology.